(Reuters) – Shares of German biotechnology firm CureVac BV CVAC.O soared as much as 222% after their Nasdaq debut on Friday, in the first stock market opening of a company developing a potential vaccine to combat the novel coronavirus. FILE PHOTO: An employee of German biopharmaceutical company CureVac, demonstrates research on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen, Germany, March 12, 2020. REUTERS/Andreas Gebert The stock opened at $44 per share and hit a session high of $51.48 in early trade, compared with the initial public offering (IPO) price of $16 per share. CureVac Chief Executive Officer Franz-Werner Haas said with the listing, the company now has about a billion euros of cash on hand to develop its vaccine candidate and to expand manufacturing capacity in order to meet global demand. “What we’ve seen so far is very promising, we are very confident.” Haas said the company expects to put its vaccine on the market by mid-2021, adding CureVac is in talks with governments around the world for potential purchase agreements. He said the company was not in talks with the White House, which on Tuesday announced a $1.5 billion deal with competitor Moderna for… Read full this story
- HIV vaccine could be available by 2021 as scientists tackling the AIDS-causing virus reveal they are 'optimistic' about three ongoing trials
- Experimental Ebola vaccine could be 'game-changer' in Congo outbreak
- SmileDirectClub makes its debut on the public market
- ‘Bayonetta 3’ Development For Nintendo Switch Moving Forward, Says Platinum Games
- Samoa measles crisis that has killed 62 people sees nation shut down with workers told to stay inside for two days and put RED FLAGS outside their homes if they need to be vaccinated
- Stocks in the news: CSB Bank, Gati, LVB, HDFC AMC, Sequent Scientific and Sical Logistics
- Ys, Legend Of Heroes Dev Exploring Possible Nintendo Switch Ports
- Experts say worst is over; bet on these 10 stocks for double-digit returns
- Malcolm Turnbull, Will Hodgman commit to getting new Bridgewater bridge built by 2024
- Daniel James completes Manchester United transfer on five-year deal
COVID-19 vaccine developer CureVac shares more than triple after U.S. debut have 330 words, post on www.reuters.com at August 14, 2020. This is cached page on Drudgereport. If you want remove this page, please contact us.